KA Kineta Corp: Bathi resik saben saham sajrone 12 wulan pungkasan

Kineta, Inc. (KA) is developing advanced immune activation methods to combat resistant tumors. However, the company faces long-term threats from funding shortages and clinical phase uncertainty. Operations within the protected environment of the US guarantee development stability. The YoY TTM EPS growth value visualizes this balance, where the parameter mark equals 80.20, cautioning investors against excessive optimism when analyzing earnings.

KA Bathi saben saham sajrone rolas wulan pungkasan Kineta Inc (11.02.2024 - 20.02.2024)

Rincian metrik keuangan lan pasar Kineta Corp (KA)

- nilai pasar lan prakiraan target analis:

Kutipan saham Kineta Inc|KA - Bagan rega target

- data kapitalisasi saham perusahaan:

Biji pasar Kineta|KA - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham Kineta|KA - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku kinetabio.com|KA - Aset Agregat Perusahaan

- indikator beban utang lan likuiditas:

- data bathi lan kelipatan valuasi:

KA - Bathi resik perusahaan|Penghasilan resik sing dikarepake Kineta, Inc.|KA - Pangali P/E|Pangali Forward P/E Kineta Corp|KA - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Kineta|KA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Kineta|KA - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan kinetabio.com|KA - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Kineta, Inc.

- rincian pendapatan lan dodolan:

KA - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Kineta|KA - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kineta|KA - Wutah pendapatan YoY sajrone 12 wulan kepungkur

Pambiji fundamental:Kineta (KA)

To protect capital amid volatility, tracking real profit dynamics is critical. This indicator captures the percentage change in net income per share over the last twelve months relative to the previous year. Analyzing the annual growth of EPS TTM allows for the identification of business scaling rates. For Kineta, Inc. (KA), this trend reflects the monetization efficiency of its immunological developments. Growth in this metric confirms the potential to secure high royalties from pharmaceutical behemoths.

Analisis pesaing Kineta, Inc.